



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-88)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	40/048,902 10/049,992
		Filing Date	October 07, 2002
		First Named Inventor	A. Beaulieu
		Group Art Unit	1646
		Examiner Name	Ostrup, Clinton T. (related case)
Sheet 1A	of 7-A	Attorney Docket Number	Beau 4 US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	39	SMAGLIK, P. "Promise and Problems Loom for Stem Cell Gene Therapy," The Scientist (1999), page 14, vol. 13, no. 15 and larger print version from The Scientist website	
	40	BROWN, C.D. et al., "A Review of Topical Agents for Wounds and Methods of Wounding-- Guidelines for Wound Management, Journal of Dermatology Surgery and Oncology, 1993, pages 732-737, vol. 19	
	41	"Carbopox® Resins -GC-67" BF Goodrich, 1990, Cleveland, OH	
	42	DORAN, J.E. et al., "Cold Insoluble Globulin-Enhanced Phagocytosis of Gelatinized Targets by Macrophage Monolayers: A Model System," Journal of the Reticuloendothelial Society, 1980, pages 471-483, vol. 27, no. 5	
	43	EDWARDS, C.A. et al., "Tri (n-Butyl) Phosphate/Detergent Treatment of Licensed Therapeutic and Experimental Blood Derivatives," Vox Sang. 1987, pages 53-59, vol. 52	
	44	HYNES, R. O., Fibronectins, 1990, Springer-Verlag	
	45	MOLNAR, J et al., "Definition of Fibronectin-mediated Uptake of Gelatinized Latex by Liver Slices and Macrophages," Biochimica et Biophysica Acta, 1987, pages 328-337, vol. 930	
	46	PIET, M.P.J. et al., "The Use of Tri (N-butyl) phosphate Detergent Mixtures to Inactivate Hepatitis Viruses and Human Immunodeficiency Virus in Plasma and Plasma's Subsequent Fractionation," 1990, Transfusion, pages 591-598, Vol 30., No. 7	
	47	RADOSEVICH, M., "Research and Development Commitments in an Integrated Plasma Collection and Plasma Fractionation Environment," Seminars in Thrombosis and Hemostasis, 1998, pages 157-161, Vol. 24, No. 2	
	48	REGNAULT, V. et al., "Preparation de fibronectine humaine de haute purete fonctionnellement active," Revue Francaise de Transfusion et Immuno-hematologie, pages 19-34, 1988, Vol. 31, No. 1 (English Abstract)	
	49	RUOSLAHTI, E. et al., "Fibronectin Purification, Immunochemical Properties, and Biological Activities," Methods in Enzymology, 1982, pages 803-831, vol. 82	

Examiner Signature		Date Considered	4/10/06
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-98)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2A of 7-A

Complete if Known

Application Number	10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	50	HARAHAP, M., "Differential Diagnosis of Leg Ulcers," Clinics in Dermatology, 1990, pages 1-3, Vol. 8, No. 3/4	
	51	HARAHAP, M., "Leg Ulcers Caused by Bacterial Infections," Clinics in Dermatology, 1990, pages 49-65, Vol. 8, No. 3/4	
	52	PHILLIPS, T.J. et al., "Leg Ulcers," Journal of the American Academy of Dermatology, 1991, pages 985-87, Vol 25, No. 6	
	53	EAGLSTEIN, W. H., "Effect of Occlusive Dressings on Wound Healing," Clinics in Dermatology, 1984, pages 107-111, Vol. 2, No. 3	
	54	EAGLSTEIN, W.H., "Current Wound Management: A Symposium," Current Wound Management, 1984, pages 134-142, Vol. 2, No. 3	
	55	EAGLSTEIN, W.H. et al., "Effect of Topically Applied Agents on Healing Wounds," Clinics in Dermatology, 1984, pages 112-115, Vol. 2, No. 3	
	56	MULDER, G.D., "Clinical Protocols for Studying Wound Healing," Clinical Materials, 1991, pages 251-255, Vol. 8	

Examiner Signature		Date Considered	4/10/06
-----------------------	--	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-86)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3A of 7-A

Complete if Known

Application Number	10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	57	SINGER, A. J. et al., "Cutaneous Wound Healing," New England Journal of Medicine, 1989, pages 738-746, Vol. 341, No. 10	
	58	CLARK, R. A. F., "Potential Roles of Fibronectin in Cutaneous Wound Repair," Arch. Dermatol., 1988, pages 201-206, Vol. 124	
	59	NORRIS, D. A. et al., "Fibronectin Fragments(s) are Chemotactic for Human Peripheral Blood Monocytes," Journal of Immunology, 1982, pages 1812-1818, Vol. 129, No. 4	
	60	CLARK, R. A. F. et al., "Cryptic Chemotactic Activity of Fibronectin for Human Monocytes Resides in the 120-kDA Fibroblastic Cell-binding Fragment," Journal of Biological Chemistry, 1988, pages 12115-12123, Vol. 263, No. 24	
	61	ALI, I. U. et al., "Effects of LETS Glycoprotein on Cell Motility," Cell, 1978, pages 439-446, Vol. 14	
	62	POSTLETHWAITE, A. E. et al., "Induction of Fibroblast Chemotaxis by Fibronectin: Localization of the Chemotactic Region to a 140,000-Molecular Weight Non-Gelatin-binding Fragment," J. Exp. Med., 1981, pages 494-499, Vol. 153	
	63	SEPPA, H. E. J. et al., "The Cell Binding Fragment of Fibronectin is Chemotactic for Fibroblasts," Cell Biology International Reports, 1981, pages 813-819, Vol. 5, No. 8	
	64	BOWERSOX, J. C. et al., "Chemotaxis of Aortic Endothelial Cells in Response to Fibronectin," Cancer Research, 1982, pages 2547-2551, Vol. 42	
	65	O'KEEFE, E. J. et al., "Production of Soluble and Cell-Associated Fibronectin by Cultured Keratinocytes," Journal of Investigative Dermatology, 1984, pages 150-155, Vol. 82, No. 2	
	66	MOSESSON, M. W. et al., "The Cold-insoluble Globulin of Human Plasma," Journal of Biological Chemistry, 1970, pages 5728-5736, Vol. 245, No. 21	
✓	67	WEISS, E. et al., "Un-Cross-Linked Fibrin Substrates Inhibit Keratinocyte Spreading and Replication: Correction with Fibronectin and Factor XIII Cross-Linking," Journal of Cellular Physiology, 1998, pages 58-65, Vol. 174	

Examiner
Signature

Date
Considered

4/10/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-88)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	10/049,992
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	October 07, 2002
		First Named Inventor	A. Beaulieu
		Group Art Unit	1646
		Examiner Name	Ostrup, Clinton T. (related case)
		Attorney Docket Number	Beau 4 US
Sheet	4A	of	7-A

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	68	CZOP, J. K., "Phagocytosis of Particulate Activators of the Alternative Complement Pathway: Effects of Fibronectin," <i>Advances in Immunology</i> , 1986, pages 361-398, Vol. 38	
	69	BEVILACQUA, M. P. et al., "Receptors for Cold-Insoluble Globulin (Plasma Fibronectin) on Human Monocytes," <i>J. Exp. Medicine</i> , 1981, pages 42-60, vol. 153	
	70	POMMIER, C. G. et al., "Plasma Fibronectin Enhances Phagocytosis of Opsonized Particles by Human Peripheral Blood Monocytes," <i>J. Exp. Medicine</i> , 1983, pages 1844-1854, Vol. 157	
	71	BROWN, E. J., "The Role of Extracellular Matrix Proteins in the Control of Phagocytosis," <i>Journal of Leukocyte Biology</i> , 1986, pages 579-591, Vol. 39	
	72	GRINNELL, F. et al., "Initial Adhesion of Human Fibroblasts in Serum-Free Medium: Possible Role of Secreted Fibronectin," <i>Cell</i> , 1979, Pages 117-129, Vol. 17	
	73	TAKASHIMA, A. et al., "Fibronectin-Mediated Keratinocyte Migration and Initiation of Fibronectin Receptor Function in Vitro," <i>Journal of Investigative Dermatology</i> , 1985, pages 304-308, Vol. 85	
	74	CLARK, R. A. F. et al., "Fibronectin, as Well as Other Extracellular Matrix Proteins, Mediate Human Keratinocyte Adherence," <i>Journal of Investigative Dermatology</i> , 1985, pages 378-383, Vol. 84	
	75	O'KEEFE, E. J. et al., "Spreading and Enhanced Motility of Human Keratinocytes on Fibronectin," <i>Journal of Investigative Dermatology</i> , 1985, pages 125-130, Vol. 85	
	76	MACARAK, E. J. et al., "Adhesion of Endothelial Cells to Extracellular Matrix Protein," <i>Journal of Cellular Physiology</i> , 1983, pages 78-88, Vol. 116	
	77	PALOTIE, A. et al., "Components of Subendothelial Aorta Basement Membrane," <i>Laboratory Investigation</i> , 1983, pages 362-370, Vol. 49, No. 3	
[Signature]	78	CLARK, R. A. F. et al., "Either Exogenous or Endogenous Fibronectin Can Promote Adherence of Human Endothelial Cells," <i>J. Cell. Sci.</i> , 1986, pages 263-280, Vol. 82	

Examiner Signature	[Signature]	Date Considered	4/10/00
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-88)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	10/049,992
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	October 07, 2002
		First Named Inventor	A. Beaulieu
		Group Art Unit	1646
		Examiner Name	Ostrup, Clinton T. (related case)
		Attorney Docket Number	Beau 4 US
Sheet	5A	of	7-A

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	79	HORSBURGH, C. R. et al., "Lymphokines and Platelets Promote Human Monocyte Adherence to Fibrinogen and Fibronectin In Vitro," Journal of Leukocyte Biology, 1987, pages 14-24, Vol. 41	
	80	GRINNELL, F. et al., "Distribution of Fibronectin During Wound Healing in Vivo," The Journal of Investigative Dermatology, 1981, pages 181-189, Vol. 78, No. 3	
	81	REPESH, L. A. et al., "Fibronectin Involvement in Granulation Tissue and Wound Healing in Rabbits," The Journal of Histochemistry and Cytochemistry, 1982, pages 351-358, Vol. 30, No. 4	
	82	CLARK, R. A. F. et al., "Fibronectin and Fibrin Provide a Provisional Matrix for Epidermal Cell Migration During Wound Reepithelialization," The Journal of Investigative Dermatology, 1982, pages 264-269, Vol. 79, No. 5	
	83	CLARK, R. A. F. et al., "Blood Vessel Fibronectin Increases in Conjunction with Endothelial Cell Proliferation and Capillary Ingrowth During Wound Healing," The Journal of Investigative Dermatology, 1982, pages 269-276, Vol. 79, No. 5	
	84	HEDMAN, K. et al., "Isolation of the Pericellular Matrix of Human Fibroblast Cultures," J. Cell Biology, 1979, pages 83-91, Vol. 81	
	85	HEDMAN, K. et al., "Structure of the Pericellular Matrix: Association of Heparan and Chondroitin Sulfates with Fibronectin-Procollagen Fibers," Cell, 1982, pages 683-671, Vol. 28	
	86	HEDMAN, K. et al., "Integrity of the Pericellular Fibronectin Matrix of Fibroblasts is Independent of Sulfated Glycosaminoglycans," The EMBO Journal, 1984, pages 581-584, Vol. 3, No. 3	
	87	CARTER, W. G., "The Role of Intermolecular Disulfide Bonding in Deposition of GP140 in the Extracellular Matrix," Journal of Cell Biology, 1984, pages 105-114, Vol. 99	
	88	CLARK, R. et al., "TGF-β1 Stimulates Cultured Human Fibroblasts to Proliferate and Produce Tissue-Like Fibroplasia: A Fibronectin Matrix-Dependent Event," Journal of Cellular Physiology, 1997, pages 69-80, Vol. 170	
	89	NAKADA, M. et al., "Efficacy of Exogenous Fibronectin in Wound Healing in Malnourished Rats," Journal of Pediatric Surgery, 1998, pages 1699-1702, Vol. 33, No. 11	

Examiner Signature		Date Considered	4/16/06
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-98)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6A of 7-A

Complete if Known

Application Number	10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	90	CHENG, C.Y. et al., "Fibronectin Enhances Healing of Excised Wounds in Rats," Arch. Dermatol., 1988, pages 221-225, Vol. 124	
	91	KONO, I. et al., "Beneficial Effect of Topical Fibronectin in Patients with Keratoconjunctivitis Sicca of Sjogren's Syndrome," Journal of Rheumatology, 1985, pages 487-489, Vol. 12	
	92	NISHIDA, T. et al., "Fibronectin Enhancement of Corneal Epithelial Wound Healing of Rabbits In Vivo," Arch. Ophthalmol., 1984, pages 455-456, Vol. 102	
	93	WHITE, H., "A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity," Econometrica, 1980, pages 817-838 Vol. 48, Issue 4	
	94	COLLETT, D., "Model Checking in the Proportional Hazards Model," Chapter 5 in Modelling Survival Data in Medical Research, 1994, 1 st edition, Chapman & Hall, London; New York	
	95	KATZ, M.H. et al., "Proportional Hazards (Cox) Regression," Journal of General Internal Medicine, 1993, pages 702-711, Vol. 8	
	96	SCHEMPER, M., "Cox Analysis of Survival Data with Non-Proportional Hazard Functions," Statistician, 1992, pages 455-465, Vol. 41, Issue 4	
	97	GREENLAND, S., "Modeling and Variable Selection in Epidemiologic Analysis," American Journal of Public Health, 1989, pages 340-349, Vol. 79, No. 3	
	98	ROBINS, J. M. et al., "The Role of Model Selection in Causal Inference from Nonexperimental Data," American Journal of Epidemiology, 1988, pages 392-402, Vol. 123, No. 3	
	99	FALANGA, V., "Care of Venous Leg Ulcers," Ostomy/Wound Management, 1999, pages 33S-43S, Vol 45 (Suppl. 1A)	
✓	100	MARGOLIS, D. et al., "Risk Factors Associated with the Failure of a Venous Leg Ulcer to Heal," Arch. Dermatol., 1999, pages 920-926, vol. 135	

Examiner
Signature


Date
Considered

4/15/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-86)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(use as many sheets as necessary)

Sheet 7A of 7-A

Complete if Known

Application Number	10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	101	MARSTON, W. A. et al., "Healing Rates and Cost Efficacy of Outpatient Compression Treatment for Leg Ulcers Associated with Venous Insufficiency," J. Vasc. Surgery, 1999, pages 491-98, Vol. 30, No. 3	
	102	OLIN, J. W. et al., "Medical Costs of Treating Venous Stasis Ulcers: Evidence from a Retrospective Cohort Study," Vascular Medicine, 1999, pages 1-7, Vol. 4	
	103	PHAN, T.-M. M. et al., "Topical Fibronectin in the Treatment of Persistent Corneal Epithelial Defects and Trophic Ulcers," American Journal of Ophthalmology, 1987, pages 494-501, Vol. 104	
	104	FLEISS, J., Statistical Methods for Rates and Proportions, 1981, pages 38-42, John Wiley and Sons, New York	
	105	LACHIN, J. M. et al., "Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification," Biometrics, 1986, pages 507-519, Vol. 42, Issue 3	
	106	HOSMER, D. et al., Applied Logistic Regression, 1989, pages 149-170, John Wiley and Sons, New York	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, this form is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1A of 7-A

Complete if Known

Application Number	10/049,002 - 10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	39	SMAGLIK, P. "Promise and Problems Loom for Stem Cell Gene Therapy," The Scientist (1999), page 14, vol. 13, no. 15 and larger print version from The Scientist website	
	40	BROWN, C.D. et al., "A Review of Topical Agents for Wounds and Methods of Wounding - Guidelines for Wound Management, Journal of Dermatology Surgery and Oncology, 1993, pages 732-737, vol. 19	
	41	"Carbopox Resins - GC-67" BF Goodrich, 1990, Cleveland, OH	
	42	DORAN, J.E. et al., "Cold Insoluble Globulin-Enhanced Phagocytosis of Gelatinized Targets by Macrophage Monolayers: A Model System," Journal of the Reticuloendothelial Society, 1980, pages 471-483, vol. 27, no. 5	
	43	EDWARDS, C.A. et al., "Tri (n-Butyl) Phosphate/Detergent Treatment of Licensed Therapeutic and Experimental Blood Derivatives," Vox Sang. 1987, pages 53-59, vol. 52	
	44	HYNES, R. O., Fibronectin, 1990, Springer-Verlag	
	45	MOLNAR, J et al., "Definition of Fibronectin-mediated Uptake of Gelatinized Latex by Liver Slices and Macrophages," Biochimica et Biophysica Acta, 1987, pages 326-337, vol. 930	
	46	PIET, M.P.J. et al., "The Use of Tri (N-butyl) phosphate Detergent Mixtures to Inactivate Hepatitis Viruses and Human Immunodeficiency Virus in Plasma and Plasma's Subsequent Fractionation," 1990, Transfusion, pages 591-598, Vol 30, No. 7	
	47	RADOSEVICH, M., "Research and Development Commitments in an Integrated Plasma Collection and Plasma Fractionation Environment," Seminars in Thrombosis and Hemostasis, 1998, pages 157-161, Vol. 24, No. 2	
	48	REGNAULT, V. et al., "Preparation de fibronectine humaine de haute purete fonctionnellement active," Revue Francaise de Transfusion et Immuno-hematologie, pages 19-34, 1988, Vol. 31, No. 1 (English Abstract)	
	49	RUOSLAHTI, E. et al., "Fibronectin Purification, Immunochemical Properties, and Biological Activities," Methods in Enzymology, 1982, pages 803-831, vol. 82	

Examiner
Signature

Date
Considered


4/10/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2A of 7-A

Complete if Known

Application Number	10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	50	HARAHAP, M., "Differential Diagnosis of Leg Ulcers," Clinics in Dermatology, 1990, pages 1-3, Vol. 8, No. 3/4	
✓	51	HARAHAP, M., "Leg Ulcers Caused by Bacterial Infections," Clinics in Dermatology, 1990, pages 49-65, Vol. 8, No. 3/4	
✓	52	PHILLIPS, T.J. et al., "Leg Ulcers," Journal of the American Academy of Dermatology, 1991, pages 965-97, Vol 25, No. 6	
✓	53	EAGLSTEIN, W. H., "Effect of Occlusive Dressings on Wound Healing," Clinics in Dermatology, 1984, pages 107-111, Vol. 2, No. 3	
✓	54	EAGLSTEIN, W.H., "Current Wound Management: A Symposium," Current Wound Management, 1984, pages 134-142, Vol. 2, No. 3	
✓	55	EAGLSTEIN, W.H. et al., "Effect of Topically Applied Agents on Healing Wounds," Clinics in Dermatology, 1984, pages 172-115, Vol. 2, No. 3	
✓	56	MULDER, G.D., "Clinical Protocols for Studying Wound Healing," Clinical Materials, 1991, pages 251-255, Vol. 8	

Examiner
Signature

Date
Considered

10/10/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (10-88)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3A of 7-A

Complete if Known

Application Number	10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>[Signature]</i>	57	SINGER, A. J. et al., "Cutaneous Wound Healing," New England Journal of Medicine, 1999, pages 738-748, Vol. 341, No. 10	
	58	CLARK, R. A. F., "Potential Roles of Fibronectin in Cutaneous Wound Repair," Arch. Dermatol., 1988, pages 201-208, Vol. 124	
	59	NORRIS, D. A. et al., "Fibronectin Fragments(s) are Chemotactic for Human Peripheral Blood Monocytes," Journal of Immunology, 1982, pages 1612-1618, Vol. 129, No. 4	
	60	CLARK, R. A. F. et al., "Cryptic Chemotactic Activity of Fibronectin for Human Monocytes Resides in the 120 kDA Fibroblastic Cell-binding Fragment," Journal of Biological Chemistry, 1988, pages 12115-12123, Vol. 263, No. 24	
	61	ALI, I. U. et al., "Effects of LETS Glycoprotein on Cell Motility," Cell, 1978, pages 439-446, Vol. 14	
	62	POSTLETHWAITE, A. E. et al., "Induction of Fibroblast Chemotaxis by Fibronectin: Localization of the Chemotactic Region to a 140,000-Molecular Weight Non-Gelatin-binding Fragment," J. Exp. Med., 1981, pages 494-499, Vol. 153	
	63	SEPPA, H. E. J. et al., "The Cell Binding Fragment of Fibronectin is Chemotactic for Fibroblasts," Cell Biology International Reports, 1981, pages 813-819, Vol. 5, No. 8	
	64	BOWERSOX, J. C. et al., "Chemotaxis of Aortic Endothelial Cells in Response to Fibronectin," Cancer Research, 1982, pages 2547-2551, Vol. 42	
	65	O'KEEFE, E. J. et al., "Production of Soluble and Cell-Associated Fibronectin by Cultured Keratinocytes," Journal of Investigative Dermatology, 1984, pages 150-155, Vol. 82, No. 2	
	66	MOSESSON, M. W. et al., "The Cold-insoluble Globulin of Human Plasma," Journal of Biological Chemistry, 1970, pages 5728-5736, Vol. 245, No. 21	
	67	WEISS, E. et al., "Un-Cross-Linked Fibrin Substrates Inhibit Keratinocyte Spreading and Replication: Correction with Fibronectin and Factor XIII Cross-Linking," Journal of Cellular Physiology, 1998, pages 58-65, Vol. 174	

Examiner
Signature

Date
Considered

4/17/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (10-86)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4A of 7-A

Complete if Known

Application Number	10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	68	CZOP, J. K., "Phagocytosis of Particulate Activators of the Alternative Complement Pathway: Effects of Fibronectin," <i>Advances in Immunology</i> , 1986, pages 361-388, Vol. 38	
	69	BEVILACQUA, M. P. et al., "Receptors for Cold-Insoluble Globulin (Plasma Fibronectin) on Human Monocytes," <i>J. Exp. Medicine</i> , 1981, pages 42-60, vol. 153	
	70	POMMIER, C. G. et al., "Plasma Fibronectin Enhances Phagocytosis of Opsonized Particles by Human Peripheral Blood Monocytes," <i>J. Exp. Medicine</i> , 1983, pages 1844-1854, Vol. 157	
	71	BROWN, E. J., "The Role of Extracellular Matrix Proteins in the Control of Phagocytosis," <i>Journal of Leukocyte Biology</i> , 1986, pages 579-591, Vol. 39	
	72	GRINNELL, F. et al., "Initial Adhesion of Human Fibroblasts in Serum-Free Medium: Possible Role of Secreted Fibronectin," <i>Cell</i> , 1978, Pages 117-129, Vol. 17	
	73	TAKASHIMA, A. et al., "Fibronectin-Mediated Keratinocyte Migration and Initiation of Fibronectin Receptor Function in Vitro," <i>Journal of Investigative Dermatology</i> , 1985, pages 304-308, Vol. 85	
	74	CLARK, R. A. F. et al., "Fibronectin, as Well as Other Extracellular Matrix Proteins, Mediate Human Keratinocyte Adherence," <i>Journal of Investigative Dermatology</i> , 1985, pages 378-383, Vol. 84	
	75	O'KEEFE, E. J. et al., "Spreading and Enhanced Motility of Human Keratinocytes on Fibronectin," <i>Journal of Investigative Dermatology</i> , 1985, pages 125-130, Vol. 85	
	76	MACARAK, E. J. et al., "Adhesion of Endothelial Cells to Extracellular Matrix Protein," <i>Journal of Cellular Physiology</i> , 1983, pages 76-86, Vol. 116	
	77	PALOTIE, A. et al., "Components of Subendothelial Aorta Basement Membrane," <i>Laboratory Investigation</i> , 1983, pages 362-370, Vol. 49, No. 3	
	78	CLARK, R. A. F. et al., "Either Exogenous or Endogenous Fibronectin Can Promote Adherence of Human Endothelial Cells," <i>J. Cell. Sci.</i> , 1986, pages 263-280, Vol. 82	

Examiner
Signature

Date
Considered


4/12/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (10-86)

Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5A of 7-A

Complete if Known

Application Number	10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	79	HORSBURGH, C. R. et al., "Lymphokines and Platelets Promote Human Monocyte Adherence to Fibrinogen and Fibronectin in Vitro," Journal of Leukocyte Biology, 1987, pages 14-24, Vol. 41	
	80	GRINNELL, F. et al., "Distribution of Fibronectin During Wound Healing in Vivo," The Journal of Investigative Dermatology, 1981, pages 181-189, Vol. 78, No. 8	
	81	REPESH, L. A. et al., "Fibronectin Involvement in Granulation Tissue and Wound Healing in Rabbits," The Journal of Histochemistry and Cytochemistry, 1982, pages 381-358, Vol. 30, No. 4	
	82	CLARK, R. A. F. et al., "Fibronectin and Fibrin Provide a Provisional Matrix for Epidermal Cell Migration During Wound Reepithelialization," The Journal of Investigative Dermatology, 1982, pages 264-269, Vol. 79, No. 5	
	83	CLARK, R. A. F. et al., "Blood Vessel Fibronectin Increases in Conjunction with Endothelial Cell Proliferation and Capillary Ingrowth During Wound Healing," The Journal of Investigative Dermatology, 1982, pages 269-276, Vol. 79, No. 5	
	84	HEDMAN, K. et al., "Isolation of the Pericellular Matrix of Human Fibroblast Cultures," J. Cell Biology, 1979, pages 83-91, Vol. 81	
	85	HEDMAN, K. et al., "Structure of the Pericellular Matrix: Association of Heparan and Chondroitin Sulfates with Fibronectin-Procollagen Fibers," Cell, 1982, pages 663-671, Vol. 28	
	86	HEDMAN, K. et al., "Integrity of the Pericellular Fibronectin Matrix of Fibroblasts is Independent of Sulfated Glycosaminoglycans," The EMBO Journal, 1984, pages 583-584, Vol. 3, No. 3	
	87	CARTER, W. G., "The Role of Intermolecular Disulfide Bonding in Deposition of GP140 in the Extracellular Matrix," Journal of Cell Biology, 1984, pages 105-114, Vol. 99	
	88	CLARK, R. et al., "TGF-β1 Stimulates Cultured Human Fibroblasts to Proliferate and Produce Tissue-Like Fibroplasia: A Fibronectin Matrix-Dependent Event," Journal of Cellular Physiology, 1997, pages 69-80, Vol. 170	
	89	NAKADA, M. et al., "Efficacy of Exogenous Fibronectin in Wound Healing in Malnourished Rats," Journal of Pediatric Surgery, 1998, pages 1699-1702, Vol. 33, No. 11	

Examiner
Signature


Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-88)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6A of 7-A

Complete if Known

Application Number	10/049,992
Filing Date	October 07, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1646
Examiner Name	Ostrup, Clinton T. (related case)
Attorney Docket Number	Beau 4 US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	90	CHENG, C. Y. et al., "Fibronectin Enhances Healing of Excised Wounds in Rats," Arch. Dermatol., 1988, pages 221-225, Vol. 124	
	91	KONO, I. et al., "Beneficial Effect of Topical Fibronectin in Patients with Keratoconjunctivitis Sicca of Sjogren's Syndrome," Journal of Rheumatology, 1985, pages 487-489, Vol. 12	
	92	NISHIDA, T. et al., "Fibronectin Enhancement of Corneal Epithelial Wound Healing of Rabbits In Vivo," Arch. Ophthalmol., 1984, pages 465-456, Vol. 102	
	93	WHITE, H., "A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity," Econometrica, 1980, pages 817-838 Vol. 48, Issue 4	
	94	COLLETT, D., "Model Checking in the Proportional Hazards Model," Chapter 5 in Modelling Survival Data in Medical Research, 1994, 1 st edition, Chapman & Hall, London; New York	
	95	KATZ, M.H. et al., "Proportional Hazards (Cox) Regression," Journal of General Internal Medicine, 1993, pages 702-711, Vol. 8	
	96	SCHEMPER, M., "Cox Analysis of Survival Data with Non-Proportional Hazard Functions," Statistician, 1992, pages 455-465, Vol. 41, Issue 4	
	97	GREENLAND, S., "Modeling and Variable Selection in Epidemiologic Analysis," American Journal of Public Health, 1989, pages 340-349, Vol. 79, No. 3	
	98	ROBINS, J. M. et al., "The Role of Model Selection in Causal Inference from Nonexperimental Data," American Journal of Epidemiology, 1986, pages 392-402, Vol. 123, No. 3	
	99	FALANGA, V., "Care of Venous Leg Ulcers," Ostomy/Wound Management, 1999, pages 33S-43S, Vol 45 (Suppl. 1A)	
[Signature]	100	MARGOLIS, D. et al., "Risk Factors Associated with the Failure of a Venous Leg Ulcer to Heal," Arch. Dermatol., 1999, pages 920-926, vol. 135	

Examiner
Signature

Date
Considered

4/16/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/049,992		
		Filing Date	October 07, 2002		
		First Named Inventor	A. Beaulieu		
		Group Art Unit	1646		
		Examiner Name	Ostrup, Clinton T. (related case)		
Sheet	7A	of	7-A	Attorney Docket Number	Beau 4 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	101	MARSTON, W. A. et al., "Healing Rates and Cost Efficacy of Outpatient Compression Treatment for Leg Ulcers Associated with Venous Insufficiency," J. Vasc. Surgery, 1999, pages 491-98, Vol. 30, No. 3	
	102	OLIN, J. W. et al., "Medical Costs of Treating Venous Stasis Ulcers; Evidence from a Retrospective Cohort Study," Vascular Medicine, 1999, pages 1-7, Vol. 4	
	103	PHAN, T.-M. M. et al., "Topical Fibrinectin in the Treatment of Persistent Corneal Epithelial Defects and Trophic Ulcers," American Journal of Ophthalmology, 1987, pages 494-501, Vol. 104	
	104	FLEISS, J., Statistical Methods for Rates and Proportions, 1981, pages 38-42, John Wiley and Sons, New York	
	105	LACHIN, J. M. et al., "Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification," Biometrics, 1986, pages 507-519, Vol. 42, issue 3	
	106	HOSMER, D. et al., Applied Logistic Regression, 1989, pages 149-170, John Wiley and Sons, New York	

Examiner Signature		Date Considered	4/10/06
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Form PTO-1449
(Modified)

Attorney Docket: Beau 2 US

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Beaulieu et al.

Serial No.: 09/331,344

Filed: August 21, 1999

Title: Wound Healing Formulations Containing Human Plasma
Fibronectin

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB- CLASS	FILING DATE

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATIONS

EXAM- INER INITIAL	DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB- CLASS	TRANS- LATION	
						YES	NO
✓ A	EP 0 312 208	4/19/89	European Patent Office	A61K	37/02		
✓ B	EP 0 592 380 A1	4/13/94	European Patent Office	A61K	37/02		
✓ C	WO 89/05653	6/29/89	World Intellectual Property Organization	A61K	37/02		
✓ D	WO 90/13653	11/15/90	World Intellectual Property Organization	C12N	15/62		
✓ E	WO 91/15233	10/17/91	World Intellectual Property Organization	A61K	37/48		
✓ F	WO 93/08825	5/13/93	World Intellectual Property Organization	A61K	37/02		

OTHER DOCUMENTS


(Including Author, Title, Date, Relevant Pages, Place of Publication)

✓ G	Devlin, TM. Textbook of Biochemistry, with Clinical Correlations. Wiley: New York, 1997. pp 6-7, 9, 34-37
✓ H	Harper, HA. Harper's Biochemistry. Appleton & Lange: Norwalk, Connecticut, 1988.
✓ I	Hynes, RO. Fibronectins. Springer-Verlag: New York, 1990. pp 12-14
✓ J	Mehninger, AT. Cell Culture: Principles and Practice. Academic Press: San Diego, 1995. pp 1-10

BEST AVAILABLE COPY

OFFICE
DEC 09 1995

L	Stryer, L. Biochemistry. W.H. Freeman: New York, 1995.
N	Van Holde, KE. Johnson, WC. Ho, PS. Principles of Biochemistry. Prentice Hall: Upper Saddle River, New Jersey, 1998. pp 16-17
O	Voet, D., Voet, Judith G. Biochemistry John Wiley & Sons, Inc. 1995. pp 72-77
P	Horowitz, B., Chang, MY. "Preparation of Fibronectin for Therapeutic Administration in Mosher, DF. Fibronectin. Academic Press: San Diego, 1989. pp 441-455
	Sibbald, RG. Ostomy/Wound Management 44(9). 1998. pp 52-58, 60-66.

Examiner: 	Date Considered: 11/18/96
---	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 2 of 2

BEST AVAILABLE COPY



Notice of References Cited

Application No. 08/767,868	Applicant(s) Beaulieu et al.
Examiner Frederick Krass	Group Art Unit 1591
Page 1 of 1	

U.S. PATENT DOCUMENTS

	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
A	4,341,784	7-1982	Wallace et al.	424	101
B					
C					
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						

NON-PATENT DOCUMENTS

	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U		
V		
W		
X		

BEST AVAILABLE COPY

(Use several sheets if necessary)

Group Art Unit	1801
----------------	------

DEC 08 2004

[illegible]

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
A	0 443 224 A1	08-28-91	Europe				
B	0 179 477 A3	04-30-86	Europe				

BEST A

DATE CONSIDERED

SHEET 1 OF 1

BEST AVAILABLE COPY

Form PTO-1449
(Modified)



UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andre Beaulieu MD FRCP(C)

Serial No.: 08/488,253

Group:

Filed: June 7, 1995

Title: WOUND HEALING FORMULATION CONTAINING
HUMAN PLASMA FIBRONECTIN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB- CLASS	FILING DATE
	A	4,455,300	06/19/84	MALLACE ET AL.	424	101	05/25/82
	B	4,740,498	04/26/88	HIRAO ET AL.	514	8	10/23/85
	C	4,925,924	05/15/90	SILVER ET AL.	510	356	10/26/87
	D	4,973,466	11/27/90	REICH	424	426	06/21/88
	E	5,045,631	09/03/91	KIMIZUKA ET AL.	530	350	02/13/89
	F	5,059,388	10/01/91	GIBSON ET AL.	514	2	06/25/90
	G	5,102,188	04/07/92	KIMIZUKA ET AL.	530	350	06/08/89
	H	5,124,155	06/23/92	REICH	424	428	09/17/90

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB- CLASS	TRANSLATIO N	
							YES	NO
	I	WO 90/08833	08/09/90	PCT				
	J	WO 92/12739	08/06/92	PCT				
	K	WO 92/13003	04/06/92	PCT				
	L	WO 91/15233	10/17/91	PCT				
	M	WO 90/06767	06/28/90	PCT				
	N	WO 90/13653	11/15/90	PCT				
	O	EP 0 314 208A1	04/19/89					
	P	EP 0 407 008A2	04/29/89					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

	Q	Hynes, R.O., Methods for identification of fibronectin (chap. 2, page 12). IN: Fibronectins New York: Springer-Verlag, 1990
	R	Hynes, R.O., Methods for identification of fibronectin (chap. 2, pages 7-23) and Wound healing, inflammation, and fibrosis (chap. 14, pages 349-64, IN: Fibronectins New York: Springer-Verlag, 1990
	S	Brothie, H., Wakefield, D. Fibronectin: Structure, function and significance in wound healing. Australas J. Dermatol 1990; 31:47-56

BEST AVAILABLE COPY

Form PTO-1449
(Modified)



UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andre Beaulieu MD FRCP (C)

Group:

Serial No.: 08/488,253

Filed: June 7, 1995

Title: WOUND HEALING FORMULATION CONTAINING
HUMAN PLASMA FIBRONECTIN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

T	Nishida, T. et al., Rapid Preparation of Purified Autologous Fibronectin Eyedrops, Jpn. J. Ophthalmol (1982) 26:416-24.
U	Phan, T. M. et al., Topical Fibronectin in the Treatment of Persistent Corneal Epithelial Defects and Trophic Ulcers, Am. J. Ophthalmol (1987) 104:494-501.
V	Wysocki, A. et al., Topical Fibronectin Therapy for Treatment of a Patient With Chronic Stasis Ulcers, Arch Dermatol (1988) 124:175-77.
W	Edwards, C.A. et al., Tri (n-butyl) Phosphate/Detergent Treated of Licensed Therapeutic and Experimental Blood Derivatives, Vox Sang (1987) 52:53-59.
X	Morowitz, B. et al., Solvent/Detergent-Treated Plasma: A Virus-Inactivated Substitute for Fresh Frozen Plasma, Blood (1992) 79:826-31.
Y	Grinnell, F. et al., Degradation of Fibronectin and Vitronectin in Chronic Wound Fluid: Analysis by Cell Blotting, Immunoblotting and Cell Adhesion Assays, J Invest Dermatol (1992) 98:410-416.
Z	Chen, W.Y.J. et al., Characterization of Biologic Properties of Wound Fluid Collected During Early Stages of Wound Healing, J Invest Dermatol (1992) 99:559-64.
AA	Berman, M. et al., Ulceration is Correlated With Degradation of Fibrin and Fibronectin at the Corneal Surface, Invest Ophthalmol Vis Sci (1983) 24:1358-66.
BB	Morowitz, W. et al., Preparation of Fibronectin for Therapeutic Administration, IN: D.F. Mosher (ed.), Fibronectin, pages 441-55, San Diego, Academic Press (1989).
CC	Franz, T.J., Percutaneous Absorption. On the Relevance of In Vitro Data, J Invest Dermatol (1975) 64:190-95.
DD	Bronaugh, R.L. et al., Methods for In Vitro Percutaneous Absorption Studies I: Comparison with In Vivo Results, Toxicol Appl Pharmacol (1982) 62:474-80.
EE	Bronaugh, R.L. et al., Methods for In Vitro Percutaneous Absorption Studies IV: The Flow-Through Diffusion Cell, J Pharm Sci (1985) 74:64-67.
FF	Saba, T.M. et al., "Prevention of Liver Reticuloendothelial Systemic Host Failure After Surgery by Intravenous Opsonic Glycoprotein Therapy," Annals of Surgery, 188:142-52 (1978).
GG	Scovill, V.A. et al., "Opsonic a ₂ Surface Binding Glycoprotein Therapy During Sepsis," Annals of Surgery, 188:521-29 (1978).
HH	Yamada, K.M. et al., "Fibronectins - Adhesive Glycoproteins of Cell Surface and Blood," Nature, 273:179-84 (1978).
II	Denaturing (SDS) Discontinuous Gel Electrophoresis: Laemmli Gel Method, pages 10.2.4 - 10.2.9, Current Protocols in Molecular Biology (1994)
JJ	Pharmaceuticals and Specialties Compendium, page 1215, Canadian Pharmaceutical Assn. (1995).

BEST AVAILABLE COPY



TO SEPARATE, HOLD TO THE TOP AND BOTTOM EDGES, SNAP-APART AND DISCARD CARBON

FORM PTO-892 (REV. 2-82)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		SERIAL NO. 08/488,253	GROUP/ART UNIT 1501	ATTACHMENT TO PAPER NUMBER		
NOTICE OF REFERENCES CITED				APPLICANT(S) Beaulieu				
U.S. PATENT DOCUMENTS								
		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE	
A		5427778	6-75	Finkbeiner et al	424	78.08		
B		4929442	5-90	Rowell	424	85.2		
C		4837019	6-87	Georgakis et al	424	101		
D								
E								
F								
G								
H								
I								
J								
K								
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS	PERTINENT SMTS. DWG. SPEC.
L								
M								
N								
O								
P								
Q								
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
R								

BEST AVAILABLE COPY

DEC 09 2005
CIP E 3017
1995, persons are required to n
TRADE MARK

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

Sheet	1	of	10
-------	---	----	----

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	100	4,001,442		Stahlberger et al.	01-04-77	
	101	4,243,656		Walliczek	01-06-81	
	102	4,347,841		Benyo et al.	09-07-82	
	103	4,369,552		Baur, Jr.	11-30-82	
	104	4,458,678		Yannas et al.	07-10-84	
	105	4,570,629		Widra	02-18-86	
	106	4,587,284		Luissi et al.	05-06-86	
	107	4,614,794		Easton et al.	09-30-86	
	108	4,664,105		Dautzenberg et al.	05-12-87	
	109	4,703,108		Silver et al.	10-27-87	
	110	4,837,285		Berg et al.	06-06-89	
	111	4,919,939		Baker	04-24-90	
	112	4,937,230		Pickart	06-26-90	
	113	4,937,323		Silver et al.	06-26-90	
	114	4,939,135		Robertson et al.	07-03-90	
	115	4,947,840		Yannas et al.	08-14-90	
	116	4,960,413		Sagar et al.	10-02-90	
	117	4,981,841		Gibson	01-01-91	
	118	4,983,580		Gibson	01-08-91	
	119	5,019,096		Fox, Jr. et al.	05-28-91	

[illegible]

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

DEC 09 2004

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

(use as many sheets as necessary)

Sheet	2	of	10
-------	---	----	----

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	120	5,045,601		Capelli et al.	09-03-91	
	121	5,053,388		Gibson et al.	10-01-91	
	122	5,064,653		Sessions et al.	11-12-91	
	123	5,076,265		Wokalek	12-31-91	
	124	5,124,392		Robertson et al.	06-23-92	
	125	5,128,321		Murray et al.	07-07-92	
	126	5,143,071		Keusch et al.	09-01-92	
	127	5,196,185		Silver et al.	03-23-93	
	128	5,196,196		Scott et al.	03-23-93	
	129	5,208,023		Hunziker	04-27-93	
	130	5,260,066		Wood et al.	11-09-93	
	131	5,270,300		Hunziker	12-14-93	
	132	5,271,939		Robertson et al.	12-21-93	
	133	5,273,900		Boyce	12-28-93	
	134	5,304,378		Koga et al.	04-18-94	
	135	5,348,939		Horowitz et al.	09-20-94	
	136	5,360,611		Robertson et al.	11-01-94	
	137	5,366,508		Brekke	11-22-94	
	138	5,368,858		Hunziker	11-29-94	
	139	5,393,602		Urry	02-28-95	

[illegible]

Date Considered

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

(use as many sheets as necessary)

Sheet	3	of	10
-------	---	----	----

Attorney Docket Number	Beau 2 US CPA CPA
------------------------	-------------------

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	140	5,395,398		Rogozinski	03-07-95	
	141	5,401,509		Robertson et al.	03-28-95	
	142	5,401,510		Robertson et al.	03-28-95	
	143	5,428,010		Murray et al.	06-27-95	
	144	5,453,482		Butzow et al.	09-26-95	
	145	5,462,536		Braatz et al.	10-31-95	
	146	5,466,462		Rosenthal et al.	11-14-95	
	147	5,480,877		Mosher, Jr. et al.	01-02-96	
	148	5,498,600		Murray et al.	03-12-96	
	149	5,514,647		Horowitz et al.	05-07-96	
	150	5,516,896		Murray et al.	05-14-96	
	151	5,520,672		Urry	05-28-96	
	152	5,525,349		Robertson et al.	06-11-96	
	153	5,534,026		Manders et al.	07-09-96	
	154	5,567,612		Vacanti et al.	10-22-96	
	155	5,573,775		Robertson et al.	11-12-96	
	156	5,580,570		Robertson et al.	12-03-96	
	157	5,582,835		Robertson et al.	12-10-96	
	158	5,589,184		Robertson et al.	12-31-96	
	159	5,589,185		Robertson et al.	12-31-96	

[illegible]

Date Considered

Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

DEC 09 2007
PATENT & TRADEMARK OFFICE

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

(use as many sheets as necessary)

Sheet	4	of	10
-------	---	----	----

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	160	5,999,558		Gordinier et al.	02-04-97	
	161	5,599,788		Purchio et al.	02-04-97	
	162	5,604,200		Taylor-McCord	02-18-97	
	163	5,604,204		Ammann et al.	02-18-97	
	164	5,605,938		Routa et al.	02-25-97	
	165	5,607,694		Marx	03-04-97	
	166	5,610,148		Brown	03-11-97	
	167	5,613,982		Goldstein	03-25-97	
	168	5,624,893		Yanni	04-29-97	
	169	5,629,287		Brown et al.	05-13-97	
	170	5,629,292		Rodgers et al.	05-13-97	
	171	5,631,011		Wadsworth	05-20-97	
	172	5,631,019		Marx	05-20-97	
	173	5,651,982		Marx	07-29-97	
	174	5,654,267		Vuori et al.	08-05-97	
	175	5,654,270		Ruoslathi et al.	08-05-97	
	176	5,654,273		Gallo et al.	08-05-97	
	177	5,665,373		Robertson et al.	09-09-97	
	178	5,672,336		Sharma	09-30-97	
	179	5,676,967		Williams et al.	10-14-97	

[illegible]

Date Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

DEC 09 2004
PATENT & TRADE OFFICE

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

(use as many sheets as necessary)

Sheet	5	of	10
-------	---	----	----

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	180	5,681,568		Goldin et al.	10-28-97	
	181	5,686,425		Lee	11-11-97	
	182	5,691,423		Smith et al.	11-25-97	
	183	5,695,777		Donovan et al.	12-9-97	
	184	5,700,476		Rosenthal et al.	12-23-97	
	185	5,703,047		Wilson	12-30-97	
	186	5,705,177		Roufa et al.	01-06-98	
	187	5,705,178		Roufa et al.	01-06-98	
	188	5,709,854		Griffith-Cima et al.	01-20-98	
	189	5,714,588		Purchio et al.	02-03-98	
	190	5,716,404		Vacanti et al.	02-10-98	
	191	5,716,935		Rodgers et al.	02-10-98	
	192	5,726,058		Jalkanen et al.	03-10-98	
	193	5,733,563		Fortier	03-31-98	
	194	5,733,884		Barbul et al.	03-31-98	
	195	5,739,113		Lee	04-14-98	
	196	5,741,685		Vacanti	04-21-98	
	197	5,744,442		Richards et al.	04-28-98	
	198	5,759,570		Arnold	06-02-98	
	199	5,763,399		Lee	06-09-98	

[illegible]**Date Considered**

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

$+$

DEC 09 2006

+

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

(use as many sheets as necessary)

Sheet	6	of	10
-------	---	----	----

U.S. PATENT DOCUMENT						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	200	5,763,416		Bonadio et al.	06-09-98	
	201	5,766,631		Arnold	06-16-98	
	202	5,787,079		Glaser et al.	06-15-98	
	203	5,770,417		Vacanti et al.	06-23-98	
	204	5,780,244		Engvall et al.	07-14-98	
	205	5,782,788		Widemire	07-21-98	
	206	5,798,118		Brown	08-25-98	
	207	5,804,178		Vacanti et al.	09-08-98	
	208	5,820,874		Mahoney et al.	10-13-98	
	209	5,827,735		Young et al.	10-27-98	
	210	5,827,826		Jaye et al.	10-27-98	
	211	5,830,504		Vuori et al.	11-03-98	
	212	5,833,665		Bootman et al.	11-10-98	
	213	5,834,418		Brazeau et al.	11-10-98	
	214	5,834,432		Rodgers et al.	11-10-98	
	215	5,837,224		Voorhees et al.	11-17-98	
	216	5,843,156		Slepian et al.	12-01-98	
	217	5,843,182		Goldstein	12-01-98	
	218	5,843,741		Wong et al.	12-01-98	
	219	5,846,604		Caldwell	12-08-98	

[illegible]

Date Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995:

Substitute for form 1449A/PTO

Complete if Known

(use as many sheets as necessary)

Sheet	7	of	10
-------	---	----	----

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind-Code ² (if known)			
	220	5,854,833		Atala	12-22-98	
	221	5,851,993		Jalkanen et al.	12-22-98	
	222	5,854,205		O'Reilly et al.	12-29-98	
	223	5,854,221		Cao et al.	12-29-98	
	224	5,855,610		Vacanti et al.	01-05-99	
	225	5,856,245		Caldwell et al.	01-05-99	
	226	5,863,984		Doillon et al.	01-26-99	
	227	5,874,164		Caldwell	02-23-99	
	228	5,891,558		Bell et al.	04-06-99	
	229	5,899,936		Goldstein	05-04-99	
	230	5,902,741		Purchio et al.	05-11-99	
	231	5,904,717		Brekke et al.	05-18-99	
	232	5,910,489		Falk et al.	06-08-99	
	233	5,919,702		Purchio et al.	07-06-99	
	234	5,928,633		Fukuyama et al.	07-27-99	
	235	5,928,635		Schmidt	07-27-99	
	236	5,932,207		Schmidt	08-03-99	
	237	5,932,552		Blanchard et al.	08-03-99	
	238	5,935,594		Ringeisen et al.	08-10-99	
	239	5,942,496		Bonadio et al.	08-24-99	

[illegible]

**Examiner
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

(use as many sheets as necessary)

Sheet	8	of	10
-------	---	----	----

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	240	5,945,403		Folkman et al.	08-31-99	
	241	5,948,432		Timmons et al.	09-07-99	
	242	5,955,430		Rodgers et al.	09-21-99	
	243	5,955,978		Pierschbacher et al.	09-21-99	
	244	5,958,874		Clark et al.	09-28-99	
	245	5,962,325		Naughton et al.	10-05-99	
	246	5,962,427		Goldstein et al.	10-05-99	
	247	5,965,125		Mineau-Hanschke	10-12-99	
	248	5,976,523		Awaya et al.	11-02-99	
	249	5,981,471		Papathanassiou et al.	11-09-99	
	250	5,981,825		Brekke	11-09-99	
	251	5,989,577		Hoath et al.	11-23-99	
	252	5,994,325		Roufa et al.	11-30-99	
	253	5,994,388		Udagawa et al.	11-30-99	
	254	6,017,727		Jalkanen et al.	01-25-00	
	255	6,020,326		Roufa et al.	02-01-00	
	256	6,024,688		Folkman et al.	02-15-00	
	257	6,037,139		Greenspan et al.	03-14-00	
	258	6,040,493		Cooke et al.	03-21-00	
	259	6,054,504		Dalla Riva Toma	04-25-00	

[illegible]**Date Considered**

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

(use as many sheets as necessary)

Sheet	9	of	10
-------	---	----	----

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	260	6,054,122		MacPhee et al.	04-25-00	
	261	6,056,970		Greenawalt et al.	05-02-00	
	262	6,071,447		Bootman et al.	06-06-00	
	263	6,074,840		Bonadio et al.	06-13-00	
	264	6,083,930		Roufa et al.	07-04-00	
	265	6,090,911		Retka et al.	07-18-00	
	266	6,093,398		Khaw et al.	07-25-00	
	267	6,106,855		Haynes et al.	08-22-00	
	268	6,110,208		Soranzo et al.	08-29-00	
	269	6,110,487		Timmons et al.	08-29-00	
	270	6,113,932		Hoath et al.	09-05-00	
	271	6,117,425		MacPhee et al.	09-12-00	
	272	6,123,957		Jernberg	09-26-00	
	273	6,124,265		Timmons et al.	09-26-00	
	274	6,124,273		Drohan et al.	09-26-00	
	275	6,127,348		Roufa et al.	10-03-00	
	276	6,129,761		Hubbell	10-10-00	
	277	6,159,495		Timmons et al.	12-12-00	
	278	6,159,496		Blanchard et al.	12-12-00	
	279	6,165,496		Timmons et al.	12-26-00	

[illegible]

Date Considered

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office.

OIP E
DEC 09 2007
PATENT & TRADEMARK OFFICE

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

(use as many sheets as necessary)

Sheet	10	of	10
-------	----	----	----

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₂
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	290	AU	573626		Johnson & Johnson	06-16-88		
	291	PCT/US	WO 00/55206	A1	Wijelath et al	09-21-00	page 25	
	292	JP	3232898	A	Takara Shuzo Co. Ltd.	10-16-91		
	293	CA	2,083,741	A1	W.R. Grace & Co.	07-25-93		
	294	PCT/GB	WO 98/00180	A1	Johnson & Johnson Medical, Inc.	01-08-98		
	295	PCT/GB	WO 98/00446	A1	Johnson & Johnson Medical, Inc.	01-08-98		
	296	EP	0901795	A2	Johnson & Johnson Medical, Inc.	03-17-99		
	297	JP	11-146909	A		06-02-99		
	298	EP	0901795	A3	Johnson & Johnson Medical, Inc.	11-29-00		

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

OIP E
 TATION
 DEC 09 2004
 PATENT & TRADEMARK OFFICE

Beau-3

08/879,159

Andre Beaulieu

June 19, 1997

1501

PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Product Information Sheet for Improved Teflon Flow-Thru Diffusion Cell— Crown Glass Company Inc.

INER**DATE CONSIDERED**

INER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and sidered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY



Notice of References Cited

Application No.
08/879,159

Applicant(s)

Beaulieu

Examiner
Frederick Krass

Group Art Unit
1614

Page 1 of 1

U.S. PATENT DOCUMENTS

	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
A	5,457,093	10-1995	Cini et al.	514	12
B	4,594,884	6-1986	Bondi et al.	73	64.3
C					
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					


FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						

NON-PATENT DOCUMENTS

	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U		
V		
V		
W		

* A copy of this reference is not being furnished with this Office action.
(See Manual of Patent Examining Procedure, Section 707.05(e).)



Notice of References Cited

Application/Control No.

09/862,971

Applicant(s)/Patent Under
Reexamination
BEAULIEU, ANDRE

Examiner

Frederick Krass

Art Unit

1614

Page 1 of 1

U.S. PATENT DOCUMENTS

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification	
A	US-6,048,337	04-2000	Svedman	604	313
B	US-				
C	US-				
D	US-				
E	US-				
F	US-				
G	US-				
H	US-				
I	US-				
J	US-				
K	US-				
L	US-				
M	US-				

FOREIGN PATENT DOCUMENTS

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
N					
O					
P					
Q					
R					
S					
T					

NON-PATENT DOCUMENTS

*	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages	
U	Chemical Abstract 110,060, "Further contribution to the absorption of the active ingredient of Arthofluor ointment" (1982)	
V		
W		
X		

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.



Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) **ET. 09 2007**

Sheet	1	of	4
-------	---	----	---

Application Number	10/145,678
Filing Date	May 15, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	Ostrup, Clinton T.
Attorney Docket Number	Beau 5

PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**


Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/145,678
Filing Date	May 15, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	Ostrup, Clinton T.
Attorney Docket Number	Beau 5

OTHER PRIOR ART - NON-PATENT LITERATURE/DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	21	DRAGET, KURT I. et al., "Alginate based new materials," International Journal of Biological Macromolecules, 1997, Vol 21, pp 47-55, Elsevier Science B.V.	
	22	PIACQUADIO, D. et al., "Alginates," J. Dermatol. Surg. Oncol. 1992 18:990-98, Elsevier Science Publishing Co., Inc.	
	23	MOE, S. et al., "Calcium Alginate Gel Fibers: Influence of Alginate Source and Gel Structure on Fiber Strength," Journal of Applied Polymer Science, 51:1771-75 (1994), John Wiley & Sons, Inc.	
	24	Pronova Biopolymer, "Dermatology and Wound Healing, History and clinical use of alginate, ..." (Date of at least January 30, 1998) Prescott Canada World Chemical Distributors, Toronto and Montreal	
	25	POTTS, J.R. et al., "Fibronectin structure and assembly," Current Opinion in Cell Biology (1994) 6:648-552	
	26	GEHRKE, S.H. et al., "Hydrogels for Drug Delivery Systems," In Specialized Drug Delivery Systems Manufacturing and Production Technology, Chapter 8, (1990) Vol. 41, pp 333-392, Marcel Dekker, New York	
	27	MUSTOE, T.A. et al., "Growth Factor-induced Acceleration of Tissue Repair through Direct and Inductive Activities in a Rabbit Dermal Ulcer Model," J. Clin Invest (1991) 87: 694-703.	
	28	KORNBLIHT et al., EMBO J. (1985) 4:1755-1759	
	29	BRADFORD, M., "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," Anal. Biochem. (1976) 72:248-254	
	30	RADOSEVICH, M., "Research and Development Commitments in an Integrated Plasma Collection and Plasma Fractionation Environment," Seminars in Thrombosis and Hemostasis. (1998) 24 (2) 157-161	
	31	HOROWITZ, B. et al., "Solvent/Detergent-Treated Plasma; A Virus-Inactivated Substitute for Fresh Frozen Plasma," Blood (1992) 79 (3):826-31	


Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


 PATENT
 DEM. 09 2005
 of 1995, no persons are required to n

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/145,678
Filing Date	May 15, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	Ostrup, Clinton T.
Attorney Docket Number	Beau 5

(use as many sheets as necessary)

Sheet	3	of	4
-------	---	----	---

[illegible][illegible]Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



+

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Send to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/145,678
Filing Date	May 15, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	Ostrup, Clinton T.
Attorney Docket Number	Beau 5

Sheet	4	of	4
-------	---	----	---

[illegible]

Date Considered

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

10/049992

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Beaulieu et al.

Serial No.: 09/331,344


Filed: August 21, 1999

Title: Wound Healing Formulations Containing Human Plasma
Fibronectin

INFORMATION DISCLOSURE STATEMENT BY APPLICANT








U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB- CLASS	FILING DATE

Examiner: 	Date Considered: 6/10/06
---	--------------------------



EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATIONS

EXAM- INER INITIAL	DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB- CLASS	TRANS- LATION
						YES NO
	A EP 0 312 208	4/19/89	European Patent Office	A61K	37/02	
	B EP 0 592 380 A1	4/13/94	European Patent Office	A61K	37/02	
	C WO 89/05653	6/29/89	World Intellectual Property Organization	A61K	37/02	
	D WO 90/13653	11/15/90	World Intellectual Property Organization	C12N	15/62	
	E WO 91/15233	10/17/91	World Intellectual Property Organization	A61K	37/48	
	F WO 93/08825	5/13/93	World Intellectual Property Organization	A61K	37/02	


OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

	G	Devlin, TM. Textbook of Biochemistry: with Clinical Correlations. Wiley: New York, 1997. pp 5-7, 9, 34-37
	H	Harper, HA. Harper's Biochemistry. Appleton & Lange: Norwalk, Connecticut, 1988
	I	Hynes, RO. Fibronectins. Springer-Verlag: New York, 1990. pp 12-14
	J	Lehninger, AL. Cox, MM. Nelson, DL. Principles of Biochemistry. Worth Publishers: New York, 1993. pp 137-143, 745
	K	Meyers, RA. Encyclopedia of molecular biology and molecular medicine. VCH Publishers: Weinheim, New York, 1996-1997. pp 282-283

10/049992

L	Stryer, L. Biochemistry. W.H. Freeman: New York, 1995.
M	Van Holde, KE. Johnson, WC. Ho, PS. Principles of Biochemistry. Prentice Hall: Upper Saddle River, New Jersey, 1998. pp 16-17
N	Voet, D., Voet, Judith G. Biochemistry John Wiley & Sons, Inc. 1995. pp. 72-77
O	Horowitz, B., Chang, MY. "Preparation of Fibronectin for Therapeutic Administration in Mosher, D. Fibronectin. Academic Press: San Diego, 1989. pp 441-455
P	Sibbald, RG. Ostomy/Wound Management 44(9). 1998. pp 52-58, 60-66.

Examiner: 	Date Considered: 4/10/00
---	--------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-86)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete If Known

Application Number	10/145,678
Filing Date	May 15, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	Ostrup, Clinton T.
Attorney Docket Number	Beau 5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
W	1	4,814,794		Easton et al.	09-30-1988	
	2	4,963,489		Naughton et al.	10-16-1990	
	3	4,970,216		Deckner et al.	11-13-1990	
	4	5,144,016		Skjak-Braek et al.	09-01-1992	
	5	5,238,685		Wren	08-24-1993	
	6	5,441,741		Cheong	08-15-1995	
	7	5,453,489		Ruostahiti et al.	09-28-1995	
	8	5,470,576		Patel	11-28-1995	
	9	5,482,932		Thompson	01-09-1996	
	10	5,514,647		Horowitz et al.	05-07-1996	
	11	5,598,084		Sanderson et al.	01-21-1997	
	12	5,674,524		Scherr	10-07-1997	
	13	5,695,777		Donovan et al.	12-09-1997	
	14	5,840,777		Eagles et al.	11-24-1998	
	15	5,922,676		Pasqualini et al.	07-13-1999	
	16	5,958,874		Clark et al.	09-28-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₀
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
W	17	EP	0721355	B1	Kershaw et al.	07-17-1996		
	18	WO	95/09658	A1	Kershaw et al.	04-13-1995		
	19	WO	96/01658	A1	Mahoney et al.	01-25-1996		
	20	WO	96/14453	A1	Mahoney et al.	05-17-1996		

Examiner Signature

Date Considered

4/6/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	101145,878- (6) 54999
Filing Date	May 15, 2002
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	Ostrup, Clinton T.
Attorney Docket Number	Beau 5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	21	DRAGET, KURT I. et al., "Alginate based new materials," International Journal of Biological Macromolecules, 1997, Vol 21, pp 47-55, Elsevier Science B.V.	
	22	PIACQUADIO, D. et al., "Alginates," J. Dermatol. Surg. Oncol. 1992 18:990-98, Elsevier Science Publishing Co., Inc.	
	23	MOE, S. et al., "Calcium Alginate Gel Fibers: Influence of Alginate Source and Gel Structure on Fiber Strength," Journal of Applied Polymer Science, 51:1771-75 (1994), John Wiley & Sons, Inc.	
	24	Pronova Biopolymer, "Dermatology and Wound Healing, History and clinical use of alginate, ..." (Date of at least January 30, 1998) Prescott Canada World Chemical Distributors, Toronto and Montreal	
	25	POTTS, J.R. et al., "Fibronectin structure and assembly," Current Opinion in Cell Biology (1994) 6:648-552	
	26	GEHRKE, S.H. et al., "Hydrogels for Drug Delivery Systems," In Specialized Drug Delivery Systems Manufacturing and Production Technology, Chapter 8, (1990) Vol. 41, pp 333-392, Marcel Dekker, New York	
	27	MUSTOE, T.A. et al., "Growth Factor-induced Acceleration of Tissue Repair through Direct and Inductive Activities in a Rabbit Dermal Ulcer Model," J. Clin Invest (1991) 87: 694-703.	
	28	KORNBLIHTT et al., EMBO J. (1985) 4:1755-1759	
	29	BRADFORD, M., "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," Anal. Biochem. (1976) 72:248-254	
	30	RADOSEVICH, M., "Research and Development Commitments in an Integrated Plasma Collection and Plasma Fractionation Environment," Seminars in Thrombosis and Hemostasis. (1998) 24 (2) 157-161	
	31	HOROWITZ, B. et al., "Solvent/Detergent-Treated Plasma; A Virus-Inactivated Substitute for Fresh Frozen Plasma," Blood (1992) 79 (3):826-31	

Examiner
Signature



Date
Considered

4/16/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

4

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/445,678 10/048992
		Filing Date	May 15, 2002
		First Named Inventor	A. Beaulieu
		Group Art Unit	1614
		Examiner Name	Ostrup, Clinton T.
Sheet	4	of	4
		Attorney Docket Number	Beau 5

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	37	BOISJOLY, H.M. "Topical Fibronectin and Aprotinin for Keratotomy Wound Healing in Rabbits," Arch. Ophthalmol. 108:1758-63 (1990)	

Examiner Signature		Date Considered	4/10/06
-----------------------	--	--------------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Complete if Known.

Application Number	08/331,344 10/049992
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

Sheet	1	of	10
-------	---	----	----

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	100	4,001,442		Stahlberger et al.	01-04-77	
	101	4,243,656		Walliczek	01-06-81	
	102	4,347,841		Benyo et al.	09-07-82	
	103	4,361,552		Baur, Jr.	11-30-82	
	104	4,458,678		Yannas et al.	07-10-84	
	105	4,570,629		Widra	02-18-86	
	106	4,587,284		Luissi et al.	05-06-86	
	107	4,614,794		Easton et al.	09-30-86	
	108	4,664,105		Dautzenberg et al.	05-12-87	
	109	4,703,108		Silver et al.	10-27-87	
	110	4,837,285		Berg et al.	06-06-89	
	111	4,919,939		Baker	04-24-90	
	112	4,937,230		Pickart	06-26-90	
	113	4,937,323		Silver et al.	06-26-90	
	114	4,939,135		Robertson et al.	07-03-90	
	115	4,947,840		Yannas et al.	08-14-90	
	116	4,960,413		Sagar et al.	10-02-90	
	117	4,981,841		Gibson	01-01-91	
	118	4,983,580		Gibson	01-08-91	
119	5,019,096		Fox, Jr. et al.	05-28-91		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ <i>(if known)</i>				
				.				
				/				

**Examiner
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet	2	of	10
-------	---	----	----

Complete if Known

Application Number	09/331,344 — 10/04992
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	120	5,045,601		Capelli et al.	09-03-91	
	121	5,053,388		Gibson et al.	10-01-91	
	122	5,064,653		Sessions et al.	11-12-91	
	123	5,076,265		Wokalek	12-31-91	
	124	5,124,392		Robertson et al.	06-23-92	
	125	5,128,321		Murray et al.	07-07-92	
	126	5,143,071		Keusch et al.	09-01-92	
	127	5,196,185		Silver et al.	03-23-93	
	128	5,196,196		Scott et al.	03-23-93	
	129	5,206,023		Hunziker	04-27-93	
	130	5,260,066		Wood et al.	11-09-93	
	131	5,270,300		Hunziker	12-14-93	
	132	5,271,939		Robertson et al.	12-21-93	
	133	5,273,900		Boyce	12-28-93	
	134	5,304,378		Koga et al.	04-19-94	
	135	5,348,939		Horowitz et al.	09-20-94	
	136	5,360,611		Robertson et al.	11-01-94	
	137	5,366,508		Brekke	11-22-94	
	138	5,368,858		Hunziker	11-29-94	
139	5,393,602		Urry	02-28-95		

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

4	10	0
---	----	---

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

$+$

+

+

+


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	3	of	10
-------	---	----	----

Application Number	09/331,344 10/049
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
J	140	5,395,398		Rogozinski	03-07-95	
	141	5,401,509		Robertson et al.	03-28-95	
	142	5,401,510		Robertson et al.	03-28-95	
	143	5,428,010		Murray et al.	06-27-95	
	144	5,453,492		Butzow et al.	09-26-95	
	145	5,462,536		Braatz et al.	10-31-95	
	146	5,466,462		Rosenthal et al.	11-14-95	
	147	5,480,877		Mosher, Jr. et al.	01-02-96	
	148	5,498,600		Murray et al.	03-12-96	
	149	5,514,647		Horowitz et al.	05-07-96	
	150	5,516,896		Murray et al.	05-14-96	
	151	5,520,672		Urry	05-28-96	
	152	5,525,349		Robertson et al.	06-11-96	
	153	5,534,026		Manders et al.	07-09-96	
	154	5,567,612		Vacanti et al.	10-22-96	
N	155	5,573,775		Robertson et al.	11-12-96	
	156	5,580,570		Robertson et al.	12-03-96	
	157	5,582,835		Robertson et al.	12-10-96	
	158	5,589,184		Robertson et al.	12-31-96	
	159	5,589,185		Robertson et al.	12-31-96	

[illegible]



✓✓✓✓	06
------	----

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	10
-------	---	----	----

Complete if Known

Application Number	09/331,344 10/049992
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
J	160	5,599,558		Gordinier et al.	02-04-97	
	161	5,599,788		Purchio et al.	02-04-97	
	162	5,604,200		Taylor-McCord	02-18-97	
	163	5,604,204		Ammann et al.	02-18-97	
	164	5,605,938		Roufa et al.	02-25-97	
	165	5,607,694		Marx	03-04-97	
	166	5,610,148		Brown	03-11-97	
	167	5,613,982		Goldstein	03-25-97	
	168	5,624,893		Yanni	04-29-97	
	169	5,629,287		Brown et al.	05-13-97	
	170	5,629,292		Rodgers et al.	05-13-97	
	171	5,631,011		Wadstrom	05-20-97	
	172	5,631,019		Marx	05-20-97	
	173	5,651,982		Marx	07-29-97	
	174	5,654,267		Vuori et al.	08-05-97	
	175	5,654,270		Ruoslahti et al.	08-05-97	
	176	5,654,273		Gallo et al.	08-05-97	
	177	5,665,373		Robertson et al.	09-09-97	
	178	5,672,336		Sharma	09-30-97	
	179	5,676,967		Williams et al.	10-14-97	

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

4/10/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344 10/049999
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

Sheet	5	of	10
-------	---	----	----

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
J	180	5,681,568		Goldin et al.	10-28-97	
	181	5,686,425		Lee	11-11-97	
	182	5,691,423		Smith et al.	11-25-97	
	183	5,695,777		Donovan et al.	12-9-97	
	184	5,700,476		Rosenthal et al.	12-23-97	
	185	5,703,047		Wilson	12-30-97	
	186	5,705,177		Roufa et al.	01-06-98	
	187	5,705,178		Roufa et al.	01-06-98	
	188	5,709,854		Griffith-Cima et al.	01-20-98	
	189	5,714,588		Purchio et al.	02-03-98	
	190	5,716,404		Vacanti et al.	02-10-98	
	191	5,716,935		Rodgers et al.	02-10-98	
	192	5,726,058		Jalkanen et al.	03-10-98	
	193	5,733,563		Fortier	03-31-98	
	194	5,733,884		Barbul et al.	03-31-98	
	195	5,739,113		Lee	04-14-98	
	196	5,741,685		Vacanti	04-21-98	
	197	5,744,442		Richards et al.	04-28-98	
	198	5,759,570		Arnold	06-02-98	
199	5,763,399		Lee	06-09-98		

[illegible]

14/10/06

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

7

of

10

~~09/331,344~~ 10/049992

10/01/01 based on 08/21/99

A. Beaulieu

1614

F. Krass

Beau 2 US CPA CPA

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
J	220	5,851,833		Atala	12-22-98	
	221	5,851,993		Jalkanen et al.	12-22-98	
	222	5,854,205		O'Reilly et al.	12-29-98	
	223	5,854,221		Cao et al.	12-29-98	
	224	5,855,610		Vacanti et al.	01-05-99	
	225	5,856,245		Caldwell et al.	01-05-99	
	226	5,863,984		Doillon et al.	01-26-99	
	227	5,874,164		Caldwell	02-23-99	
	228	5,891,558		Bell et al.	04-06-99	
	229	5,899,936		Goldstein	05-04-99	
	230	5,902,741		Purchio et al.	05-11-99	
	231	5,904,717		Brekke et al.	05-18-99	
	232	5,910,489		Falk et al.	06-08-99	
	233	5,919,702		Purchio et al.	07-06-99	
	234	5,928,633		Fukuyama et al.	07-27-99	
	235	5,928,635		Schmidt	07-27-99	
	236	5,932,207		Schmidt	08-03-99	
	237	5,932,552		Blanchard et al.	08-03-99	
	238	5,935,594		Ringeisen et al.	08-10-99	
239	5,942,496		Bonadio et al.	08-24-99		

[illegible]

4	10	26
---	----	----

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

10

Complete if Known

Application Number

~~09/331.344~~ 13/049992

Filing Date

10/01/01 based on 08/21/99

First Named Inventor

A. Beaulieu

Group Art Unit

1614

Examiner Name

F. Krass

Attorney Docket Number

Beau 2 US CPA CPA

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
19	240	5,945,403		Folkman et al.	08-31-99	
	241	5,948,432		Timmons et al.	09-07-99	
	242	5,955,430		Rodgers et al.	09-21-99	
	243	5,955,978		Pierschbacher et al.	09-21-99	
	244	5,958,874		Clark et al.	09-28-99	
	245	5,962,325		Naughton et al.	10-05-99	
	246	5,962,427		Goldstein et al.	10-05-99	
	247	5,965,125		Mineau-Hanschke	10-12-99	
	248	5,976,523		Awaya et al.	11-02-99	
	249	5,981,471		Papathanassiou et al.	11-09-99	
	250	5,981,825		Brekke	11-09-99	
	251	5,989,577		Hoath et al.	11-23-99	
	252	5,994,325		Roufa et al.	11-30-99	
	253	5,994,388		Udagawa et al.	11-30-99	
	254	6,017,727		Jalkanen et al.	01-25-00	
	255	6,020,326		Roufa et al.	02-01-00	
	256	6,024,688		Folkman et al.	02-15-00	
	257	6,037,139		Greenspan et al.	03-14-00	
	258	6,040,493		Cooke et al.	03-21-00	
259	6,054,504		Dalla Riva Toma	04-25-00		

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 10

Complete if Known

Application Number	09/331,344- 10/84999
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	260	6,054,122		MacPhee et al.	04-25-00	
	261	6,056,970		Greenawalt et al.	05-02-00	
	262	6,071,447		Bootman et al.	06-06-00	
	263	6,074,840		Bonadio et al.	06-13-00	
	264	6,083,930		Roufa et al.	07-04-00	
	265	6,090,911		Petka et al.	07-18-00	
	266	6,093,398		Khaw et al.	07-25-00	
	267	6,106,855		Haynes et al.	08-22-00	
	268	6,110,208		Soranzo et al.	08-29-00	
	269	6,110,487		Timmons et al.	08-29-00	
	270	6,113,932		Hoath et al.	09-05-00	
	271	6,117,425		MacPhee et al.	09-12-00	
	272	6,123,957		Jernberg	09-26-00	
	273	6,124,265		Timmons et al.	09-26-00	
	274	6,124,273		Drohan et al.	09-26-00	
	275	6,127,348		Roufa et al.	10-03-00	
	276	6,129,761		Hubbell	10-10-00	
	277	6,159,495		Timmons et al.	12-12-00	
	278	6,159,496		Blanchard et al.	12-12-00	
	279	6,165,496		Timmons et al.	12-26-00	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	280	JP	5178897	A	Takara Shuzo Co Ltd.	07-20-93		
	281	DE	19905128	A1	Schering AG	08-10-00		
	282	EP	0179477	A	Green Cross Corp.	4-30-86		
	283	EP	0278103	A	American Cyanamid Co.	8-17-88		

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office.

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/331,344 <i>10/249,992</i>
Filing Date	10/01/01 based on 08/21/99
First Named Inventor	A. Beaulieu
Group Art Unit	1614
Examiner Name	F. Krass
Attorney Docket Number	Beau 2 US CPA CPA

(use as many sheets as necessary)

Sheet	10	of	10
-------	----	----	----

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
JP	290	AU	573626		Johnson & Johnson	06-16-88	page 25	
	291	PCT/ US	WO 00/55206	A1	Wijelath et al.	09-21-00		
	292	JP	3232898	A	Takara Shuzo Co. Ltd.	10-16-91		
	293	CA	2,083,741	A1	W.R. Grace & Co.	07-25-93		
	294	PCT/ GB	WO 98/00180	A1	Johnson & Johnson Medical, Inc.	01-08-98		
	295	PCT/ GB	WO 98/00446	A1	Johnson & Johnson Medical, Inc.	01-08-98		
	296	EP	0901795	A2	Johnson & Johnson Medical, Inc.	03-17-99		
	297	JP	11-146909	A		06-02-99		
	298	EP	0901795	A3	Johnson & Johnson Medical, Inc.	11-29-00		

**Examiner
Signature**

Date .
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449
(Modified)

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andre Beaulieu MD FRCP(C)

Serial No.: 08/488,253

Group:

Filed: June 7, 1995

Title: WOUND HEALING FORMULATION CONTAINING
HUMAN PLASMA FIBRONECTIN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB- CLASS	FILING DATE
	A	4,455,300	06/19/84	MALLACE ET AL.	424	101	05/25/82
	B	4,740,498	04/26/88	MIRAO ET AL.	514	8	10/23/85
	C	4,925,924	05/15/90	SILVER ET AL.	530	356	10/26/87
	D	4,973,466	11/27/90	REICH	424	426	06/21/88
	E	5,045,631	09/03/91	KINIZUKA ET AL.	530	350	02/13/89
	F	5,053,388	10/01/91	GIBSON ET AL.	514	2	06/25/90
	G	5,102,988	04/07/92	KINIZUKA ET AL.	530	350	06/08/89
	H	5,124,155	06/23/92	REICH	424	428	09/17/90

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB- CLASS	TRANSLATIO N	
							YES	NO
	I	WO 90/08833	08/09/90	PCT				
	J	WO 92/12739	08/06/92	PCT				
	K	WO 92/13003	08/06/92	PCT				
	L	WO 91/15233	10/17/91	PCT				
	M	WO 90/06767	06/28/90	PCT				
	N	WO 90/11653	11/15/90	PCT				
	O	EP 0 312 208A1	04/19/89					
	P	EP 0 407 008A2	04/29/89					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

	Q	Hynes, R.O., Methods for identification of fibronectin (chap. 2, page 12), IN: Fibronectins New York: Springer-Verlag, 1990
	R	Hynes, R.O., Methods for identification of Fibronectin (chap. 2, pages 7-23) and Wound healing, inflammation, and fibrosis (chap. 14, pages 349-64, IN: Fibronectins New York: Springer-Verlag, 1990
	S	Brotchie, H., Wakefield, D. Fibronectin: Structure, function and significance in wound healing. Australas J. Dermatol 1990; 31:47-56

Examiner:

Date Considered:

EXAMINER: INITIAL CITATION CONSIDERED. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449
(Modified)

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andre Beaulieu MD FRCP (C)

Group:

Serial No.: 08/488,253

10/049992

Filed: June 7, 1995

Title: WOUND HEALING FORMULATION CONTAINING
HUMAN PLASMA FIBRONECTIN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

T	Wishida, T. et al., Rapid Preparation of Purified Autologous Fibronectin Eyedrops, Jpn. J. Ophthalmol (1982) 26:416-24.
U	Phan, T. M. et al., Topical Fibronectin in the Treatment of Persistent Corneal Epithelial Defects and Trophic Ulcers, Am. J. Ophthalmol (1987) 104:494-501.
V	Wysocki, A. et al., Topical Fibronectin Therapy for Treatment of a Patient With Chronic Stasis Ulcers, Arch Dermatol (1988) 124:175-77.
W	Edwards, C.A. et al., Tri (n-butyl) Phosphate/Detergent Treated of Licensed Therapeutic and Experimental Blood Derivatives, Vox Sang (1987) 52:53-59.
X	Morowitz, B. et al., Solvent/Detergent-Treated Plasma: A Virus-Inactivated Substitute for Fresh Frozen Plasma, Blood (1992) 79:826-31.
Y	Grimwell, F. et al., Degradation of Fibronectin and Vitronectin in Chronic Wound Fluid: Analysis by Cell Blotting, Immunoblotting and Cell Adhesion Assays, J Invest Dermatol (1992) 98:410-416.
Z	Chen, W.Y.J. et al., Characterization of Biologic Properties of Wound Fluid Collected During Early Stages of Wound Healing, J Invest Dermatol (1992) 99:559-64.
AA	Berman, M. et al., Ulceration is Correlated With Degradation of Fibrin and Fibronectin at the Corneal Surface, Invest Ophthalmol Vis Sci (1983) 24:1358-66.
BB	Morowitz, N. et al., Preparation of Fibronectin for Therapeutic Administration, IN: D.F. Mosher (ed.), Fibronectin, pages 441-55, San Diego, Academic Press (1989).
CC	Franz, T.J., Percutaneous Absorption. On the Relevance of In Vitro Data, J Invest Dermatol (1975) 64:190-95.
DD	Bronaugh, R.L. et al., Methods for In Vitro Percutaneous Absorption Studies I: Comparison with In Vivo Results, Toxicol Appl Pharmacol (1982) 62:474-80.
EE	Bronaugh, R.L. et al., Methods for In Vitro Percutaneous Absorption Studies IV: The Flow-Through Diffusion Cell, J Pharm Sci (1985) 74:64-67.
FF	Saba, T.M. et al., "Prevention of Liver-Baticuloendothelial Systemic Host Failure After Surgery by Intravenous Opsonic Glycoprotein Therapy," Annals of Surgery, 188:142-52 (1978).
GG	Scovill, W.A. et al., "Opsonic Surface Binding Glycoprotein Therapy During Sepsis," Annals of Surgery, 188:521-29 (1978).
HH	Yamada, K.M. et al., "Fibronectins - Adhesive Glycoproteins of Cell Surface and Blood," Nature, 273:179-84 (1978).
II	Denaturing (SDS) Discontinuous Gel Electrophoresis: Laemmli Gel Method, pages 10.2.4 - 10.2.9, Current Protocols in Molecular Biology (1994)
JJ	Pharmaceuticals and Specialities Compendium, page 1215, Canadian Pharmaceutical Assn. (1995).

Examiner:

Date Considered:

4/10/96

EXAMINER: INITIAL CITATION CONSIDERED. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED.
INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

TO SEPARATE, HOLD TOP AND BOTTOM EDGES, SNAP-APART AND DISCARD CARBON

10/04999~

FORM PTO-892 (REV. 2-92)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		SERIAL NO. 08/488,253	GROUP/ART UNIT 1501	ATTACHMENT TO PAPER NUMBER 3
NOTICE OF REFERENCES CITED				APPLICANT(S) Beaulieu		

U.S. PATENT DOCUMENTS												
	DOCUMENT NO.							DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
A	5	4	2	7	7	7	8	6-95	Finkbeiner et al	424	78.08	
B	4	9	2	9	4	4	2	5-90	Powell	424	85.2	
C	4	8	3	7	0	1	9	6-89	Georgelas et al	424	101	
D												
E												
F												
G												
H												
I												
J												
K												

FOREIGN PATENT DOCUMENTS													
	DOCUMENT NO.							DATE	COUNTRY	NAME	CLASS	SUB-CLASS	PERTINENT SMTS. DWG. PP. SPEC.
L													
M													
N													
O													
P													
Q													

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	
R	
S	
T	
U	

VICKIE KIM
PRIMARY EXAMINER

EXAMINER 	DATE 10/15	4/10/06
--------------	---------------	---------

* A copy of this reference is not being furnished with this office action.
(See Manual of Patent Examining Procedure, section 707.05 (a).)

(Use several sheets if necessary)

BEAU-1

~~08/488,253~~

Andre Beaulieu

June 7, 1995

1501

[illegible]

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
A	0 443 224 A1	08-28-91	Europe				
B	0 179 477 A3	04-30-86	Europe				

DATE CONSIDERED

SHEET 1 OF 1

10/4991~

Notice of References Cited

Application No.
08/167,868

Applicant(s)

Beaulieu et al.

Examiner

Frederick Krass

Group Art Unit

1501

Page 1 of 1

U.S. PATENT DOCUMENTS

	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
A	4,341,764	7-1982	Wallace et al.	424	101
B				----	----
C					
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						

NON-PATENT DOCUMENTS

	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U		
V		
W		
X		

VICKIE KIM
PRIMARY EXAMINER

10/24/91

Notice of References Cited

Application No.
08/879,159

Applicant(s)

Beaulieu

Examiner

Frederick Krass

Group Art Unit
1614

Page 1 of 1


U.S. PATENT DOCUMENTS

	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
A	5,457,093	10-1995	Cini et al.	514	12
B	4,594,884	6-1986	Bondi et al.	73	64.3
C					
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						

NON-PATENT DOCUMENTS

	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U		
V		
W	VICKIE KIM PRIMARY EXAMINER	
X	<i>Exam.</i>  <i>SJK: 4/6/96</i>	

* A copy of this reference is not being furnished with this Office action.
(See Manual of Patent Examining Procedure, Section 707.05(a).)

Notice of References Cited

Application/Control No.

09/862,971

Applicant(s)/Patent Under
Reexamination
BEAULIEU, ANDRE

Examiner

Frederick Krass

Art Unit

1614

Page 1 of 1

U.S. PATENT DOCUMENTS

* /	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification	
A	US-6,048,337	04-2000	Svedman	604	313
B	US-				
C	US-				
D	US-				
E	US-				
F	US-				
G	US-				
H	US-				
I	US-				
J	US-				
K	US-				
L	US-				
M	US-				

FOREIGN PATENT DOCUMENTS

* /	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification	
N						
O						
P						
Q						
R						
S						
T						

NON-PATENT DOCUMENTS

* /	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages				
U	Chemical Abstract 110,060, "Further contribution to the absorption of the active ingredient of Arthofluor ointment" (1982)				
V					
W					
X					

VICKIE KIM
PRIMARY EXAMINER

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.